Literature DB >> 15258564

Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro.

Mohammad R Abedini1, Qing Qiu, Xiaojuan Yan, Benjamin K Tsang.   

Abstract

Chemoresistance is a major therapeutic problem and the current knowledge on cellular mechanisms involved is incomplete. In the present study, we have investigated the possible involvement of Fas-associated death domain-like interleukin-1beta-converting enzyme (FLICE)-like inhibitory protein (FLIP) in ovarian cancer resistance by comparing chemosensitive (OV2008) and chemoresistant (C13*) ovarian cancer cells treated with cisplatin in vitro, and/or transfected with FLIP sense cDNA or FLIP small interfering RNA (siRNA) and determining FLIP protein content, cleavage of caspase-8 and caspase-3 and apoptosis. Cisplatin significantly decreased FLIP protein level, induced cleavage of caspase-8 and caspase-3 and apoptosis in a concentration-dependent manner in cisplatin-sensitive but not -resistant cells. While overexpression of FLIP-attenuated cisplatin-induced cleavage of caspase-8 and caspase-3 and apoptosis in chemosensitive cells, downregulation of FLIP in chemoresistant cells by siRNA increased apoptosis induced by cisplatin. These results suggest that FLIP plays a significant role in the regulation of apoptosis in human ovarian cancer cells and their sensitivity to cisplatin. This cell survival factor may be an important determinant in chemoresistance in ovarian cancer and may serve as a molecular target for the development of novel therapy for chemoresistant ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258564     DOI: 10.1038/sj.onc.1207925

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.

Authors:  Wei-Wei Pan; Jian-Jie Zhou; Chao Yu; Ying Xu; Lian-Jun Guo; Hai-Yi Zhang; Dawang Zhou; Fang-Zhou Song; Heng-Yu Fan
Journal:  J Biol Chem       Date:  2013-08-30       Impact factor: 5.157

2.  Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Authors:  Karen Bräutigam; Julia Biernath-Wüpping; Dirk O Bauerschlag; Constantin S von Kaisenberg; Walter Jonat; Nicolai Maass; Norbert Arnold; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

3.  Effect of sodium chloride on efficiency of cisplatinum dissolved in dimethyl sulfoxide: an in vitro study.

Authors:  Seyed Kazem Bagherpour Doun; Sohrab Halal Khor; Dardi Qujeq; Hasan Ebrahimi Shahmabadi; Seyed Ebrahim Alavi; Fatemeh Movahedi; Azim Akbarzadeh
Journal:  Indian J Clin Biochem       Date:  2013-07-10

4.  The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.

Authors:  Songqing Fan; Yikun Li; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

5.  Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.

Authors:  Shuzhen Chen; Wei Cao; Ping Yue; Chunhai Hao; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

Review 6.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

7.  p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.

Authors:  Bao Kong; Qi Wang; Ella Fung; Kai Xue; Benjamin K Tsang
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

8.  Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.

Authors:  Wei-Wei Pan; Jian-Jie Zhou; Xiao-Man Liu; Ying Xu; Lian-Jun Guo; Chao Yu; Qing-Hua Shi; Heng-Yu Fan
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

Review 9.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

Review 10.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.